Chemical Library - COVID 19 Action
Closed Special Notice Posted
This opportunity was awarded. See the award notice from .
- Solicitation number
- NCATS-21-005414
- Agency
- National Institute on Drug Abuse National Institutes of Health, Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6810 Chemicals
- Place of performance
- Bethesda, Maryland 20892, United States
Notice details come from SAM.gov. Updated .
About this opportunity
This Special Notice from the Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse announces their intent to award a sole source contract to Medkoo, Inc. for provision of a pre-clinical screening library of small molecules. The library is required to support screening efforts at the National Institutes of Health's National Center for Advancing Translational Services.
The Notice provides interested contractors until July 22, 2021 to submit capability statements for consideration, however the agency reserves the right to proceed with a non-competitive sole source award to Medkoo, Inc. The library must contain fourteen specific small molecule compounds with validated biological activity available for high-throughput and high-content screening, accompanied by detailed reports. The resulting contract would have a period of performance from August 15, 2021 through January 14, 2022. To be eligible, contractors must have an active System for Award Management registration and submit responses referencing the solicitation number by the stated deadline and in Microsoft Word or PDF format not exceeding ten pages.
Notice text
2 versions
Update #2 · Latest ·
NOTICE OF INTENT to Sole Source
Amended 7-22-21
The Library of Small Molecules that will be purchased has been expound and is displayed in the chart below. The Salient Characteristics have also been amended. The updated PD has been uploaded to reflect these changes.
1. SOLICITATION NUMBER:
NIMH-21-005414
TITLE: Chemical Library
2. CLASSIFICATION CODE:
6810– Chemical Compounds
3. NAICS CODE: 325412 – Pharmaceutical Preparation Manufacturing
4. RESPONSE DATE:
July 22, 2021 at 3:00 PM EST
5. PRIMARY POINT OF CONTACT:
Michelle Cecilia
Michelle.cecilia@nih.gov
Phone: (301) 827-7199
6. DESCRIPTION:
INTRODUCTION
THIS IS A PRE-SOLICITATION NON-COMPETITIVE (NOTICE OF INTENT) SYNOPSIS TO AWARD A CONTRACT WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME).
The National Institutes of Health, National Center for Advancing Translational Services intends to negotiate on a sole source basis with Medkoo, Inc. for its pre-clinical screening library of small molecules
NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODE and SET ASIDE STATUS
The intended procurement is classified under 325412 –Pharmaceutical Preparation Manufacturing Size Standard of 1,250 employees.
REGULATORY AUTHORITY
This acquisition is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13—Simplified Acquisition Procedures. Contracts awarded using FAR Part 13—Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6—Competition Requirements. FAR Subpart 13.106-1 (b) Soliciting from a single source provides that: For purchases not exceeding the simplified acquisition threshold, Contracting officers may solicit from one source IF the contracting officer determines that the circumstances of the contract action deem only one source reasonably available (e.g., urgency, exclusive licensing agreements, brand-name OR industrial mobilization).
The resultant contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 2021-06 dated June 10, 2021.
BACKGROUND, PURPOSE AND OBJECTIVES OF REQUIREMENT
Independently and not as an agent of the Government, the Contractor shall furnish all the necessary services, qualified personnel, material, equipment, and facilities, not otherwise provided by the Government as needed to perform.
Screening is often the starting point in our development and a wealth of knowledge is obtained from screening a diverse collection. It provides the starting point of all information for medicinal chemistry’s structure-activity relationship (SAR) design to synthesize novel compounds that have more desirable properties. A diverse and novel screening collection provides the backbone of our operation and is imperative for translational sciences to obtain effective small molecules with on-target effects.
These small molecules have been designed around analysis of available chemical and biological information, identification of key pathways modules/targets, computational and “wet biology” assessment of target druggability and potential binding domains. The resulting information is analyzed by synthetic and medicinal chemistry teams to bring new chemical diversity and to design unique scaffolds that are likely to interact with the designated targets yielding focused compound libraries. Having such small molecules will make a huge impact in our screening against the variety of targets that NCATS works on and will also help tremendously in bioinformatics analysis which will allow a more thorough and effective SAR expansion by the medicinal chemist.
Immediate Delivery
6. Salient characteristics:
• Small molecules must have validated biological and pharmacological activities.
• Must be available for high-throughput screening (HTS) and high-content screening (HCS).
• Must come with detailed biological and chemical information with LC/MS and NMR reports to ensure high quality.
• Each small molecule must be guaranteed to have a purity of >95% (accuracy +/-5%) that is to be confirmed by NMR and/or LCMS spectra.
• In addition to the molecules themselves, the Contractor must be able to provide the following electronic information for each required molecule: chemical structure or simplified molecular-input line-entry system (SMILES) or equivalent chemical structure information, supplier ID, plate ID, well location, tube ID, concentration in millimolar, and volume in microliters. This information shall be provided via email referencing individual compound vial barcodes.
7. Quantity:
See Amended PD for Compounds and Quanitities
Period of Performance:
August 15, 2021 – January 14, 2022
CONTRACTING WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME) DETERMINATION
The intended source is:
MedKoo, Inc.
2500 Gateway Center Blvd, Suite 400
Morrisville, NC 27560
CLOSING STATEMENT
THIS SYNOPSIS IS NOT A REQUEST FOR COMPETITIVE PROPOSALS. However, interested parties may identify their interest and capability to respond to this notice.
A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. All responsible sources may submit a capability statement, proposal, or quotation which shall be considered by the agency. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement.
Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov.
One (1) copy of the response is required and must be in Microsoft Word or Adobe PDF format using 11 point or 12 point font, 8-1 /2" x 11" paper size, with 1" top, bottom, left and right margins, and with single or double spacing. The response is limited to ten (10) page limit. The 10-page limit does not include the cover page, executive summary, or references, if requested.
All responses must be received by the closing date and time of this announcement and must reference the solicitation number, NIMH-21-005414. Responses must be submitted electronically to Michelle Cecilia, Contract Specialist, at michelle.cecilia@nih.gov. U.S. Mail and fax responses will not be accepted.
Update #1 ·
NOTICE OF INTENT to Sole Source
1. SOLICITATION NUMBER:
NIMH-21-005414
TITLE: Chemical Library
2. CLASSIFICATION CODE:
6810– Chemical Compounds
3. NAICS CODE: 325412 – Pharmaceutical Preparation Manufacturing
4. RESPONSE DATE:
July 22, 2021 at 3:00 PM EST
5. PRIMARY POINT OF CONTACT:
Michelle Cecilia
Michelle.cecilia@nih.gov
Phone: (301) 827-7199
6. DESCRIPTION:
INTRODUCTION
THIS IS A PRE-SOLICITATION NON-COMPETITIVE (NOTICE OF INTENT) SYNOPSIS TO AWARD A CONTRACT WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME).
The National Institutes of Health, National Center for Advancing Translational Services intends to negotiate on a sole source basis with Medkoo, Inc. for its pre-clinical screening library of small molecules
NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODE and SET ASIDE STATUS
The intended procurement is classified under 325412 –Pharmaceutical Preparation Manufacturing Size Standard of 1,250 employees.
REGULATORY AUTHORITY
This acquisition is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13—Simplified Acquisition Procedures. Contracts awarded using FAR Part 13—Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6—Competition Requirements. FAR Subpart 13.106-1 (b) Soliciting from a single source provides that: For purchases not exceeding the simplified acquisition threshold, Contracting officers may solicit from one source IF the contracting officer determines that the circumstances of the contract action deem only one source reasonably available (e.g., urgency, exclusive licensing agreements, brand-name OR industrial mobilization).
The resultant contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 2021-06 dated June 10, 2021.
BACKGROUND, PURPOSE AND OBJECTIVES OF REQUIREMENT
Independently and not as an agent of the Government, the Contractor shall furnish all the necessary services, qualified personnel, material, equipment, and facilities, not otherwise provided by the Government as needed to perform.
Screening is often the starting point in our development and a wealth of knowledge is obtained from screening a diverse collection. It provides the starting point of all information for medicinal chemistry’s structure-activity relationship (SAR) design to synthesize novel compounds that have more desirable properties. A diverse and novel screening collection provides the backbone of our operation and is imperative for translational sciences to obtain effective small molecules with on-target effects.
These small molecules have been designed around analysis of available chemical and biological information, identification of key pathways modules/targets, computational and “wet biology” assessment of target druggability and potential binding domains. The resulting information is analyzed by synthetic and medicinal chemistry teams to bring new chemical diversity and to design unique scaffolds that are likely to interact with the designated targets yielding focused compound libraries. Having such small molecules will make a huge impact in our screening against the variety of targets that NCATS works on and will also help tremendously in bioinformatics analysis which will allow a more thorough and effective SAR expansion by the medicinal chemist.
• MedKoo Cat#: 205802, Name: 4SC-203, CAS#: 895533-09-2
• MedKoo Cat#: 571354, Name: Abecarnil, CAS#: 111841-85-1
• MedKoo Cat#: 319754, Name: Abediterol, CAS#: 915133-65-2
• MedKoo Cat#: 571381, Name: Ablukast, CAS#: 96566-25-5
• MedKoo Cat#: 531380, Name: ABT-384, CAS#: 868623-40-9
• MedKoo Cat#: 205897, Name: AC430, CAS#: 1361415-84-0
• MedKoo Cat#: 563998, Name: Aclimostat, CAS#: 2082752-83-6
• MedKoo Cat#: 571533, Name: ACT-451840, CAS#: 1839508-99-4
• MedKoo Cat#: 319692, Name: Deleobuvir, CAS#: 863884-77-9
• MedKoo Cat#: 524344, Name: AZD-4818, CAS#: 1003566-93-5
• MedKoo Cat#: 414172, Name: Exeporfinium bromide, CAS#: 943326-71-4
• MedKoo Cat#: 564872, Name: Hetrombopag, CAS#: 1257792-41-8
• MedKoo Cat#: 576394, Name: HSD-016, CAS#: 946396-92-5
• MedKoo Cat#: 461814, Name: Sari 59-801, CAS#: 80565-58-8
6. Salient characteristics:
- Small molecules must have validated biological and pharmacological activities.
- Must be available for high-throughput screening (HTS) and high-content screening (HCS).
- Must come with detailed biological and chemical information with LC/MS and NMR reports to ensure high quality.
7. Quantity:
• One (1) 4SC-203, 1.0g
• One (1) Abecarnil, 1.0g
• One (1) Abediterol, 1.0g
• One (1) Ablukast, 1.0g
• One (1) ABT-384, 1.0g
• One (1) AC430, 1.0g
• One (1) ACT-451840, 1.0g
• One (1) Deleobuvir, 1.0g
• One (1) AZD-4818, 1.0g
• One (1) Exeporfinium bromide, 1.0g
• One (1) Hetrombopag, 1.0g
• One (1) HSD-016, 1.0g
• One (1) Sari 59-801, 1.0g
Period of Performance:
August 15, 2021 – January 14, 2022
CONTRACTING WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME) DETERMINATION
The intended source is:
MedKoo, Inc.
2500 Gateway Center Blvd, Suite 400
Morrisville, NC 27560
CLOSING STATEMENT
THIS SYNOPSIS IS NOT A REQUEST FOR COMPETITIVE PROPOSALS. However, interested parties may identify their interest and capability to respond to this notice.
A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. All responsible sources may submit a capability statement, proposal, or quotation which shall be considered by the agency. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement.
Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov.
One (1) copy of the response is required and must be in Microsoft Word or Adobe PDF format using 11 point or 12 point font, 8-1 /2" x 11" paper size, with 1" top, bottom, left and right margins, and with single or double spacing. The response is limited to ten (10) page limit. The 10-page limit does not include the cover page, executive summary, or references, if requested.
All responses must be received by the closing date and time of this announcement and must reference the solicitation number, NIMH-21-005414. Responses must be submitted electronically to Michelle Cecilia, Contract Specialist, at michelle.cecilia@nih.gov. U.S. Mail and fax responses will not be accepted.
Attachments
| File | Type | Posted |
|---|---|---|
| Amended PD 7_27-21.pdf |
Notice history
| Notice | Type | Posted |
|---|---|---|
| Chemical Library - COVID 19 Action | Award Notice | |
| Chemical Library - COVID 19 Action | Special Notice |
On GovTribe
Work this opportunity on GovTribe
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity